An interventional study of Emsella chair in Benign Prostatic Hyperplasia, Enlarged Prostate With Lower Urinary Tract Symptoms and Enlarged Prostate (BPH), sponsored by Northwestern University. Enrolling by invitation at 1 site in United States. Open to male participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Northwestern University · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Prostatic Hyperplasia by Northwestern University — 4 open to participants now, 5 under way, none of them phase 3. Prostatic Hyperplasia · Northwestern University.
Among the 10 studies in Prostatic Hyperplasia by Northwestern University, this one is one of 3 that started in 2026, is one of 7 with no phase, and was the 7th registered.
831 studies on the registry are indexed under Prostatic Hyperplasia; 180 are open to participants now.
Browse Prostatic Hyperplasia studies →4 of the 10 studies in Prostatic Hyperplasia by Northwestern University are open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 18–100 · Men only · Healthy volunteers
Northwestern University · Sites in United States
Ages 18–100 · Men only · Healthy volunteers
Northwestern University · Sites in United States
Ages 50+ · Men only
By country, each count listing its studies:
Of the 103 Prostatic Hyperplasia studies recruiting now, 70 (68%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 50 Years to 80 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 94 across 629 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 48 across the 9 interventional studies, 300 across the 1 observational. Of the 5 that completed or were terminated, 4 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
Northwestern University is the lead sponsor of 1,424 studies on the registry; 199 are open to participants now.
Of its 105 completed or terminated interventional studies of FDA-regulated products, 78 (74%) have results posted.
4 of the studies in Prostatic Hyperplasia by Northwestern University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05898932Northwestern UniversityEnhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes | 2027-04 |
| NCT07631286Northwestern UniversityEjaculatory-Sparing HoLEP vs Standard HoLEP | 2027-05 |
| NCT07632742Northwestern UniversityMoses 2.0 vs Magneto for HoLEP - a Randomized Controlled Trial | 2027-06 |
| NCT07580404Northwestern UniversityEmsella for Reducing tSUI After HOLEP | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 10 studies in Prostatic Hyperplasia by Northwestern University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to investigate the effectiveness of the Emsella chair treatments at different timepoints. Before and after the holmium laser enucleation of the prostate (HoLEP).
Emsella is a non-invasive treatment used to activate and strengthen the pelvic floor. One Emsella treatment is reported to be the equivalent of performing 11,000 Kegel exercises. This study aims to examine the effectiveness of Emsella chair treatments in reducing the likelihood of tSUI following HoLEP by comparing the outcomes of patients who completed treatments at different points of time around their HoLEP procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients are reminded to perform pelvic floor exercises known as Kegel exercises for 3 weeks leading up to their scheduled HoLEP procedure, and continue Kegel exercises for 3 weeks following the HoLEP procedure.
Participants will complete 2 30-minute Emsella treatment sessions for 3 weeks (for a total of 6 30-minute Emsella chair treatment sessions) leading up to their scheduled HoLEP procedure. They will undergo the HoLEP 1 week after the final Emsella treatment session.
Device: Emsella chair
Participants will complete 2 30-minute Emsella treatment sessions for 3 weeks (for a total of 6 30-minute Emsella chair treatment sessions) following their scheduled HoLEP procedure. They will begin their first Emsella treatment session 1 week after HoLEP.
Device: Emsella chair
Emsella is a non-invasive treatment used to activate and strengthen the pelvic floor. One Emsella treatment is reported to be the equivalent of performing 11,000 Kegel exercises.
Difference in Michigan Incontinence Score (M-ISI)
The Michigan Incontinence Score (M-ISI) is a 10-item questionnaire designed to assess urinary incontinence type, severity, and bother, with a focus on stress and urge incontinence. The tool is commonly used to screen for clinically relevant symptoms, with a total score of greater than or equal to 7 suggesting a need for intervention.
Time frame: Pre-HoLEP, 4 weeks, 6 weeks, 8 weeks, 12 weeks post-HoLEP
Difference in International Prostate Symptom Score (IPSS)
The International Prostate Symptom Score (IPSS) is a 7-question tool (0-35 points) used in urology to assess Benign Prostatic Hyperplasia (BPH) severity, plus one quality-of-life question. It measures symptoms like frequency, urgency, weak stream, and nocturia, with scores of 0-7 (Mild), 8-19 (Moderate), and 20-35 (Severe).
Time frame: Pre-HoLEP, 4 weeks, 6 weeks, 8 weeks, 12 weeks post-HoLEP
Difference in safety/adverse effects
Adverse effects reported by patient or detected from hospital and ER admissions within 3 months after procedure.
Time frame: 12 weeks post-HoLEP
Difference in patient reported symptoms
Patient reported symptoms via REDCap surveys related to gross hematuria, dysuria, incontinence after HoLEP.
Time frame: 6 months post-HoLEP
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Jul 2027, 12 months after the start.
Of 155 non-industry interventional studies with no phase under Prostatic Hyperplasia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 48. This study's planned 12 months is below that.
Counting every sponsor, half of 207 studies reached it within 27 months; a quarter within 15 and three quarters within 48.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: start Jun 2026 → Jul 2026, primary completion Jun 2027 → Jul 2027 and completion Jun 2028 → Jul 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.